DOCSLIB.ORG

Provider Type 20 Physician, MD., Osteopath Reimbursement Rates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Provider Type 20 Physician, MD., Osteopath Reimbursement Rates Provider Type 20 Physician, MD., Osteopath Reimbursement Rates Updated: July 1, 2015 The information contained in the schedule is made available to provide information and is not a guarantee by the State or the Department or its employees as to the present accuracy of the information contained herein. For example, coverage as well as an actual rate may have been revised or updated and may no longer be the same as posted on the website. Note: Procedure codes with a rate of $0.00 are reimbursed at 62% of Usual and Customary charges unless noted otherwise in Nevada Medicaid policy. CPT codes, descriptions and other data only are copyright © 2008 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CPT is a registered trademark ® of the American Medical Association. Current Dental Terminology, fourth edition (CDT) (including procedure codes, definitions (descriptors) and other data) is copyrighted by the American Dental Association. © 2008 American Dental Association. All rights reserved. Applicable FARS/DFARS apply. Proc Code Description Mod Rate 01953 ANESTH BURN EACH 9 PERCENT 21.12 01996 HOSP MANAGE CONT DRUG ADMIN 63.36 0359T BEHAVIORAL ID ASSESSMENT 70.19 0360T OBSERV BEHAV ASSESSMENT 70.19 0361T OBSERV BEHAV ASSESS ADDL 70.19 0362T EXPOSE BEHAV ASSESSMENT 70.19 0363T EXPOSE BEHAV ASSESS ADDL 70.19 0364T ADAPTIVE BEHAVIOR TREATMENT 60.20 0365T ADAPTIVE BEHAVIOR TX ADDL 60.20 0366T GROUP BEHAVIOR TREATMENT 42.84 0367T GROUP BEHAV TREATMENT ADDL 42.84 0368T BEHAVIOR TREATMENT MODIFIED 60.20 0369T BEHAV TREATMENT MODIFY ADDL 60.20 0370T FAM BEHAV TREATMENT GUIDANCE 84.68 0372T SOCIAL SKILLS TRAINING GROUP 42.84 0373T EXPOSURE BEHAVIOR TREATMENT 76.28 0374T EXPOSE BEHAV TREATMENT ADDL 76.28 10021 FNA W/O IMAGE 70.92 10022 FNA W/IMAGE 65.39 10030 Guide cathet fluid drainage 154.73 10040 ACNE SURGERY 87.47 10060 DRAINAGE OF SKIN ABSCESS 95.60 10061 DRAINAGE OF SKIN ABSCESS 178.04 10080 DRAINAGE OF PILONIDAL CYST 103.29 Proc Code Description Mod Rate 10081 DRAINAGE OF PILONIDAL CYST 172.45 10120 REMOVE FOREIGN BODY 103.22 10121 REMOVE FOREIGN BODY 185.58 10140 DRAINAGE OF HEMATOMA/FLUID 118.06 10160 PUNCTURE DRAINAGE OF LESION 95.62 10180 COMPLEX DRAINAGE WOUND 178.97 11000 DEBRIDE INFECTED SKIN 28.42 11001 DEBRIDE INFECTED SKIN ADD-ON 14.22 11004 DEBRIDE GENITALIA & PERINEUM 579.35 11005 DEBRIDE ABDOM WALL 781.65 11006 DEBRIDE GENIT/PER/ABDOM WALL 702.26 11008 REMOVE MESH FROM ABD WALL 274.06 11010 DEBRIDE SKIN AT FX SITE 278.30 11011 DEBRIDE SKIN MUSC AT FX SITE 301.71 11012 DEB SKIN BONE AT FX SITE 426.17 11042 DEB SUBQ TISSUE 20 SQ CM/< 61.54 11043 DEB MUSC/FASCIA 20 SQ CM/< 157.36 11044 DEB BONE 20 SQ CM/< 234.59 11045 DEB SUBQ TISSUE ADD-ON 27.63 11046 DEB MUSC/FASCIA ADD-ON 56.21 11047 DEB BONE ADD-ON 100.66 11055 TRIM SKIN LESION 15.90 11056 TRIM SKIN LESIONS 2 TO 4 22.47 11057 TRIM SKIN LESIONS OVER 4 29.39 11100 BIOPSY SKIN LESION 48.61 11101 BIOPSY SKIN ADD-ON 24.46 11200 REMOVAL OF SKIN TAGS <W/15 73.00 11201 REMOVE SKIN TAGS ADD-ON 16.77 11300 SHAVE SKIN LESION 0.5 CM/< 34.94 11301 SHAVE SKIN LESION 0.6-1.0 CM 53.11 11302 SHAVE SKIN LESION 1.1-2.0 CM 62.20 11303 SHAVE SKIN LESION >2.0 CM 74.11 11305 SHAVE SKIN LESION 0.5 CM/< 38.48 11306 SHAVE SKIN LESION 0.6-1.0 CM 51.56 11307 SHAVE SKIN LESION 1.1-2.0 CM 66.25 11308 SHAVE SKIN LESION >2.0 CM 72.94 11310 SHAVE SKIN LESION 0.5 CM/< 47.19 11311 SHAVE SKIN LESION 0.6-1.0 CM 65.00 11312 SHAVE SKIN LESION 1.1-2.0 CM 78.37 11313 SHAVE SKIN LESION >2.0 CM 100.38 11400 EXC TR-EXT B9+MARG 0.5 CM< 79.32 11401 EXC TR-EXT B9+MARG 0.6-1 CM 103.18 11402 EXC TR-EXT B9+MARG 1.1-2 CM 113.71 11403 EXC TR-EXT B9+MARG 2.1-3CM/< 146.50 11404 EXC TR-EXT B9+MARG 3.1-4 CM 160.82 11406 EXC TR-EXT B9+MARG >4.0 CM 244.91 Proc Code Description Mod Rate 11420 EXC H-F-NK-SP B9+MARG 0.5/< 81.23 11421 EXC H-F-NK-SP B9+MARG 0.6-1 110.40 11422 EXC H-F-NK-SP B9+MARG 1.1-2 134.86 11423 EXC H-F-NK-SP B9+MARG 2.1-3 156.55 11424 EXC H-F-NK-SP B9+MARG 3.1-4 178.52 11426 EXC H-F-NK-SP B9+MARG >4 CM 273.01 11440 EXC FACE-MM B9+MARG 0.5 CM/< 103.53 11441 EXC FACE-MM B9+MARG 0.6-1 CM 131.15 11442 EXC FACE-MM B9+MARG 1.1-2 CM 145.52 11443 EXC FACE-MM B9+MARG 2.1-3 CM 177.64 11444 EXC FACE-MM B9+MARG 3.1-4 CM 226.95 11446 EXC FACE-MM B9+MARG >4 CM 326.08 11450 REMOVAL SWEAT GLAND LESION 250.45 11451 REMOVAL SWEAT GLAND LESION 323.33 11462 REMOVAL SWEAT GLAND LESION 239.27 11463 REMOVAL SWEAT GLAND LESION 326.52 11470 REMOVAL SWEAT GLAND LESION 281.55 11471 REMOVAL SWEAT GLAND LESION 352.30 11600 EXC TR-EXT MAL+MARG 0.5 CM/< 119.51 11601 EXC TR-EXT MAL+MARG 0.6-1 CM 148.23 11602 EXC TR-EXT MAL+MARG 1.1-2 CM 162.64 11603 EXC TR-EXT MAL+MARG 2.1-3 CM 194.07 11604 EXC TR-EXT MAL+MARG 3.1-4 CM 214.78 11606 EXC TR-EXT MAL+MARG >4 CM 319.34 11620 EXC H-F-NK-SP MAL+MARG 0.5/< 121.29 11621 EXC S/N/H/F/G MAL+MRG 0.6-1 148.93 11622 EXC S/N/H/F/G MAL+MRG 1.1-2 170.68 11623 EXC S/N/H/F/G MAL+MRG 2.1-3 211.61 11624 EXC S/N/H/F/G MAL+MRG 3.1-4 239.93 11626 EXC S/N/H/F/G MAL+MRG >4 CM 294.83 11640 EXC F/E/E/N/L MAL+MRG 0.5CM< 125.18 11641 EXC F/E/E/N/L MAL+MRG 0.6-1 155.98 11642 EXC F/E/E/N/L MAL+MRG 1.1-2 183.25 11643 EXC F/E/E/N/L MAL+MRG 2.1-3 230.87 11644 EXC F/E/E/N/L MAL+MRG 3.1-4 285.84 11646 EXC F/E/E/N/L MAL+MRG >4 CM 397.05 11719 TRIM NAIL(S) ANY NUMBER 7.60 11720 DEBRIDE NAIL 1-5 14.90 11721 DEBRIDE NAIL 6 OR MORE 24.56 11730 REMOVAL OF NAIL PLATE 50.53 11732 REMOVE NAIL PLATE ADD-ON 20.06 11740 DRAIN BLOOD FROM UNDER NAIL 32.76 11750 REMOVAL OF NAIL BED 173.14 11752 REMOVE NAIL BED/TIP 259.66 11755 BIOPSY NAIL UNIT 78.21 11760 REPAIR OF NAIL BED 133.87 Proc Code Description Mod Rate 11762 RECONSTRUCTION OF NAIL BED 185.05 11765 EXCISION OF NAIL FOLD TOE 93.04 11770 REMOVE PILONIDAL CYST SIMPLE 183.77 11771 REMOVE PILONIDAL CYST EXTEN 431.80 11772 REMOVE PILONIDAL CYST COMPL 573.13 11900 INJECT SKIN LESIONS </W 7 31.12 11901 INJECT SKIN LESIONS >7 48.63 11950 TX CONTOUR DEFECTS 1 CC/< 53.20 11951 TX CONTOUR DEFECTS 1.1-5.0CC 76.48 11952 TX CONTOUR DEFECTS 5.1-10CC 100.70 11954 TX CONTOUR DEFECTS >10.0 CC 116.38 11960 INSERT TISSUE EXPANDER(S) 934.51 11970 REPLACE TISSUE EXPANDER 616.24 11971 REMOVE TISSUE EXPANDER(S) 322.25 11976 REMOVE CONTRACEPTIVE CAPSULE 97.05 11980 IMPLANT HORMONE PELLET(S) 79.88 11981 INSERT DRUG IMPLANT DEVICE 81.34 11982 REMOVE DRUG IMPLANT DEVICE 97.30 11983 REMOVE/INSERT DRUG IMPLANT 168.65 12001 RPR S/N/AX/GEN/TRNK 2.5CM/< 45.00 12002 RPR S/N/AX/GEN/TRNK2.6-7.5CM 59.25 12004 RPR S/N/AX/GEN/TRK7.6-12.5CM 73.87 12005 RPR S/N/A/GEN/TRK12.6-20.0CM 99.98 12006 RPR S/N/A/GEN/TRK20.1-30.0CM 121.24 12007 RPR S/N/AX/GEN/TRNK >30.0 CM 150.62 12011 RPR F/E/E/N/L/M 2.5 CM/< 56.15 12013 RPR F/E/E/N/L/M 2.6-5.0 CM 62.72 12014 RPR F/E/E/N/L/M 5.1-7.5 CM 79.77 12015 RPR F/E/E/N/L/M 7.6-12.5 CM 99.25 12016 RPR FE/E/EN/L/M 12.6-20.0 CM 134.79 12017 RPR FE/E/EN/L/M 20.1-30.0 CM 154.16 12018 RPR F/E/E/N/L/M >30.0 CM 174.32 12020 CLOSURE OF SPLIT WOUND 190.75 12021 CLOSURE OF SPLIT WOUND 141.38 12031 INTMD RPR S/A/T/EXT 2.5 CM/< 152.69 12032 INTMD RPR S/A/T/EXT 2.6-7.5 193.83 12034 INTMD RPR S/TR/EXT 7.6-12.5 206.50 12035 INTMD RPR S/A/T/EXT 12.6-20 242.75 12036 INTMD RPR S/A/T/EXT 20.1-30 281.53 12037 INTMD RPR S/TR/EXT >30.0 CM 329.21 12041 INTMD RPR N-HF/GENIT 2.5CM/< 156.10 12042 INTMD RPR N-HF/GENIT2.6-7.5 199.13 12044 INTMD RPR N-HF/GENIT7.6-12.5 215.46 12045 INTMD RPR N-HF/GENIT12.6-20 270.64 12046 INTMD RPR N-HF/GENIT20.1-30 307.30 12047 INTMD RPR N-HF/GENIT >30.0CM 342.23 Proc Code Description Mod Rate 12051 INTMD RPR FACE/MM 2.5 CM/< 171.16 12052 INTMD RPR FACE/MM 2.6-5.0 CM 202.59 12053 INTMD RPR FACE/MM 5.1-7.5 CM 217.62 12054 INTMD RPR FACE/MM 7.6-12.5CM 229.00 12055 INTMD RPR FACE/MM 12.6-20 CM 304.25 12056 INTMD RPR FACE/MM 20.1-30.0 378.07 12057 INTMD RPR FACE/MM >30.0 CM 380.17 13100 CMPLX RPR TRUNK 1.1-2.5 CM 205.67 13101 CMPLX RPR TRUNK 2.6-7.5 CM 253.35 13102 CMPLX RPR TRUNK ADDL 5CM/< 74.94 13120 CMPLX RPR S/A/L 1.1-2.5 CM 236.18 13121 CMPLX RPR S/A/L 2.6-7.5 CM 266.90 13122 CMPLX RPR S/A/L ADDL 5 CM/> 86.11 13131 CMPLX RPR F/C/C/M/N/AX/G/H/F 250.46 13132 CMPLX RPR F/C/C/M/N/AX/G/H/F 314.11 13133 CMPLX RPR F/C/C/M/N/AX/G/H/F 131.55 13151 CMPLX RPR E/N/E/L 1.1-2.5 CM 287.17 13152 CMPLX RPR E/N/E/L 2.6-7.5 CM 348.07 13153 CMPLX RPR E/N/E/L ADDL 5CM/< 142.39 13160 LATE CLOSURE OF WOUND 812.08 14000 TIS TRNFR TRUNK 10 SQ CM/< 503.62 14001 TIS TRNFR TRUNK 10.1-30SQCM 653.91 14020 TIS TRNFR S/A/L 10 SQ CM/< 570.41 14021 TIS TRNFR S/A/L 10.1-30 SQCM 718.98 14040 TIS TRNFR F/C/C/M/N/A/G/H/F 634.12 14041 TIS TRNFR F/C/C/M/N/A/G/H/F 777.02 14060 TIS TRNFR E/N/E/L 10 SQ CM/< 675.50 14061 TIS TRNFR E/N/E/L10.1-30SQCM 831.27 14301 TIS TRNFR ANY 30.1-60 SQ CM 885.86 14302 TIS TRNFR ADDL 30 SQ CM/< 222.91 14350 FILLETED FINGER/TOE FLAP 710.79 15002 WOUND PREP TRK/ARM/LEG 228.12 15003 WOUND PREP ADDL 100 CM 45.82 15004 WOUND PREP F/N/HF/G 273.12 15005 WND PREP F/N/HF/G ADDL CM 92.01 15040 HARVEST CULTURED SKIN GRAFT 127.99 15050 SKIN PINCH GRAFT 447.97 15100 SKIN SPLT GRFT TRNK/ARM/LEG 721.11 15101 SKIN SPLT GRFT T/A/L ADD-ON 111.59 15110 EPIDRM AUTOGRFT TRNK/ARM/LEG 755.76 15111 EPIDRM AUTOGRFT T/A/L ADD-ON 102.43 15115 EPIDRM A-GRFT FACE/NCK/HF/G 760.07 15116 EPIDRM A-GRFT F/N/HF/G ADDL 135.54 15120 SKN SPLT A-GRFT FAC/NCK/HF/G 704.54 15121 SKN SPLT A-GRFT F/N/HF/G ADD 132.65 15130 DERM AUTOGRAFT TRNK/ARM/LEG 572.46 Proc Code Description Mod Rate 15131 DERM AUTOGRAFT T/A/L ADD-ON 93.99 15135 DERM AUTOGRAFT FACE/NCK/HF/G 751.60 15136 DERM AUTOGRAFT F/N/HF/G ADD 85.38 15150 CULT SKIN GRFT T/ARM/LEG 628.41 15151 CULT SKIN GRFT T/A/L ADDL 109.41 15152 CULT SKIN GRAFT T/A/L
Load more

Recommended publications
  • View Our Annual Report
    2015 Surgery Report Inova Fairfax Medical Campus 2015 Surgery Report Table of Contents Inova Fairfax Medical Campus 1 Welcome 3 Education 5 Quality and Patient Safety 6 ASTEC 8 Research 9 Midlevel Clinical Practice Providers 10 Surgery Department Administration 11 Surgical Department Organizational Chart 13 Surgical Specialty Areas 24 Surgery by the Numbers 26 Selected Honors, Presentations, Publications and Research Mission Statement John J. Moynihan, MD, FACS Chairman, Department of Surgery To work collaboratively with the entire Associate Professor, VCU School of Medicine - Inova Campus healthcare team to provide the highest quality, most innovative and effective patient-centered surgical care to the diverse population we serve In 2015, the Inova Fairfax Medical Campus Department of Surgery had another Inova “Vision 2020” is to exciting and successful year. Build the Future of Health: The dedication and determination of our surgeons resulted in significant progress in the department’s mission to deliver world-class patient care, conduct 1 We will reinvent hospital-based care to cutting edge research in a multidisciplinary fashion and provide state-of-the-art increase value for our patients undergraduate and graduate medical education. 2 We will look outside our hospitals to build an integrated network of facilities, In addition to advancing surgical care through adoption of new technologies, the providers and programs to support our members of the department continue to be strong advocates for improvements community in the quality of care and the experience of patients who receive their care at our 3 We will gain national and international institution. recognition and funding – as well as an Recognition of the accomplishments of our department’s surgeons at regional, expanded patient base – through world- national and international levels further promotes the widespread value of the work renowned specialty care and leading-edge our surgeons are doing.
    [Show full text]
  • 2014 Final Program
    INTERNATIONAL FEDERATION OF HEAD AND NECK ONCOLOGIC SOCIETIES 5th World Congress of IFHNOS & Annual Meeting of the AHNS AMERICAN HEAD AND NECK SOCIETY Celebrating the 100th Anniversary of the Head and Neck Program at Memorial Sloan-Kettering Cancer Center July 26-30, 2014 Marriott Marquis, New York City, NY The Largest Head and Neck Cancer Congress in History A Century of Progress in Head and Neck Cancer HOSTED BY: ORGANIZED & SPONSORED BY: SUPPORTED BY: FINAL PROGRAM WORLD CONGRESS ON LARYNX CANCER 2015 SAVE THE DATE! To view the provisional program visit www.wclc2015.org KEyNoTE ToPiCS: • Larynx cancer and its place in history • Non-open laryngeal surgery including robots • The patient as a variable in defining outcome • Voice restoration/preservation • Clinical trials and larynx cancer • Reconstruction • Pre-malignant lesions • Radiotherapy-where to for the future • Staging and surgical anatomy • Poor prognostic factors for survival • Voice assessment methods and function • Molecular biology and translational • Chemotherapy-good to use alone? research • Swallowing assessment/ • Public health issues around the rehabilitation world including the status of anti-smoking campaigns in China • Transplant • Patient support structures • Survivorship • Databases • Larynx cancer in the developing world Further information: T: +61 3 9249 1273 E: [email protected] VISIBILITY DONORS Thank you to our 2014 Visibility Donors! The following companies have provided generous support for non-CME meeting activities. DIAMOND DONORS Ethicon US, LLC IBM Watson Medtronic Surgical Technologies PLATINUM DONORS Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals IRX Therapeutics, Inc. Merck KGaA GOLD DONORS Bristol-Myers Squibb Exelixis SILVER DONORS Covidien Medrobotics Veracyte BRONZE DONOR Olympus America Inc.
    [Show full text]
  • Surgery Notes IIIII a PPROACH to ABDOMINAL MASSES 1111 IV IV OESOPHAGEAL DISEASES 1212
    CONTENTS Page I TRAUMA (MULTI-SPECIALTY APPROACH) 22 IIII APPROACH TO ABDOMINAL PAIN 1100 Surgery Notes IIIII A PPROACH TO ABDOMINAL MASSES 1111 IIVV OESOPHAGEAL DISEASES 1122 For the M.B.B.S. VV UPPER BLEEDING GIT AND ITS CAUSES 2211 VVII COLORECTAL DISEASES 1199 By Andre Tan VII LIVER DISEASES 3399 VIII PANCREA TIC DISEASES 4455 IIXX BILIARY TRACT DISEASES 5511 XX BREAST DISEASES 6600 XXII HEAD AND NECK MASSES 6699 XII SALIVARY GLAND SWELLINGS 7744 XIII THYROID DISEASES 7788 XIV PERIPHERAL ARTERIAL DISEASE 8855 XV ABDOMINAL AORTIC ANEURYSM 9933 XVI PERIPHERAL VENOUS DISEASE 9955 XVII UROLOGICAL DISEASES 9999 XVIII SURGICAL INSTRUMENTS 111100 TRAUMA (MULTI-SPECIALTY APPROACH) Management o f breathing -- Supplemental oxygen -- Ventilate as required if patient requires assistance with breathing AADVANCED TTRAUMA LLIFEIFE SSUPPORT ALGORITHM -- Needle thoracotomy for tension pneumothorax, followed by chest tube MAIN PRINCIPLES: -- Occlusive dressing for open pneumothorax -- Treat greatest threat to life first -- Definitive diagnosis is less important 3.3. CIRCULATION -- Time is important – – the “golden hour” after trauma is when 30% of trauma deaths Assessment of organ perfusion occur, and are preventable by ATLS -- Level of consciousness -- Skin colour and temperature, capillary refill -- Pulse rate and character – – all major pulses APPROACH -- Blood pressure 1.1. Primary survey and Resuscitation with adjuncts 2.2. Re-evaluation of the patient Classes of haemorrhagic shock 3.3. Secondary survey with adjuncts I II III IVIV 4.4. Post-resuscitation monitoring and re-evaluation Bld loss 5.5. Optimise for transfer and definitive care Amt (ml) <750 750-1500 1500-2000 >2000 Percentage <15<15 15-30 30-40 >40>40 Ht rate <100 >100 >120 >140 PRIMARY SURVEY – – ABCDE BPBP Normal Normal Decreased Decreased Cap refill Normal Prolonged Prolonged Prolonged 1.1.
    [Show full text]
  • Sialoendoscopy-Assisted Sialolithectomy for Submandibular
    J Oral Maxillofac Surg 71:295-301, 2013 Sialoendoscopy-Assisted Sialolithectomy for Submandibular Hilar Calculi Deng-Gao Liu, SMD,* Lan Jiang, SMD,† Xiao-Yan Xie, SMD,‡ Zu-Yan Zhang, DDS, PhD,§ Lei Zhang, SMD,ʈ and Guang-Yan Yu, PhD, DDS¶ Purpose: To assess the clinical effects of endoscopy-assisted sialolithectomy for submandibular hilar calculi. Materials and Methods: The present study was undertaken in 70 patients with symptomatic stones in the hilum of submandibular glands who underwent endoscopy-assisted sialolithectomy from Decem- ber 2005 through March 2011 in the Peking University School and Hospital of Stomatology. The operative data were analyzed retrospectively. All patients were followed periodically postoperatively. Submandib- ular gland function was investigated by postoperative symptoms, clinical examinations, sialography, and scintigraphy. Results: Submandibular stones were successfully removed in 65 patients, with a success rate of 92.9%. Temporary lingual nerve injury occurred in 1 patient. Two patients developed ranulae and underwent an uneventful sublingual gland excision. During a mean follow-up of 23 months (range, 6 to 55 mo), 52 of 65 patients were symptom free, whereas 11 patients complained of occasional swelling of the affected gland at mealtimes and 2 patients developed a recurrent stone. Thirty patients underwent postoperative sialography. The sialographic appearances included 4 types: 1) approximately normal; 2) the main duct was significantly dilated at the hilum, but no persistent contrast was seen on the functional film; 3) the main duct was significantly dilated in the hilar region, and persistent contrast was seen at the dilated hilum of the functional film; 4) the main duct was dilated or strictured, and persistent contrast was seen on the functional film.
    [Show full text]
  • Classic Approaches to Sialoendoscopy for Treatment of Sialolithiasis ODED NAHLIELI
    7 Classic Approaches to Sialoendoscopy for Treatment of Sialolithiasis ODED NAHLIELI Obstructive sialadenitis, with or without sialolithiasis, sialoadenitis. These data do not include patients who represents the main inflammatory disorder of the major were treated as ambulatory (outpatient) cases. salivary glands. The diagnosis and treatment of obstruc- There is a male preponderance,5 and the peak tions and inflammations of these glands can be proble- incidence is between the ages of 30 and 60.5 Sialoliths matic due to the limitations of standard imaging grow by deposition and range in size from 0.1 to techniques. Satisfactory treatment depends on our 30 mm.6 Presentation is typically with a painful swelling ability to reach a precise diagnosis and, in the case of of the gland at meal times, when the obstruction caused sialoliths, to accurately locate the obstruction. Until by the calculus becomes most acute.7 recently many of these glands required complete During the past decade, with the introduction of removal under general anesthesia. salivary gland endoscopy there has been a major step Sialolithiasis is a common finding, accounting for forward, not only in providing an accurate means of 50% of major salivary gland disease.1,2 The subman- diagnosing and locating intraductal obstructions, but dibular gland is the most prone to sialolithiasis. In also in permitting minimally invasive surgical treatment various studies it was found that Â/80% of all sialo- that can successfully manage those blockages that are lithiasis cases are in the submandibular glands, 19% not accessible intraorally.8 Á20 occur in the parotid gland, and Â/1% are found in the sublingual gland.
    [Show full text]
  • Sialendoscopy-Approaches to Parotid Duct and Gland-Lecture-10
    11/6/2014 Sialoendoscopic Approaches to the Parotid Duct and Gland For Sialadentis / Sialolithiasis Disclosures William Ryan, MD Assistant Professor Head and Neck Oncologic/Endocrine/Salivary Surgery Consultant for Medtronic Department of Otolaryngology-Head and Neck Surgery Transoral Open Sialodochotomy / Sialodochoplasty Transoral Open Sialodochotomy / Sialodochoplasty Distal Stones / Stenosis Transoral Sialendoscopy Transoral Sialendoscopy Middle Duct - Hilar Stones / Stenosis Transfacial Open Duct Surgery (+/- Sialendoscopy) Transfacial Open Duct Surgery (+/- Sialendoscopy) Impacted Stones / > 5-7mm Stones / Parenchymal stones Failed Sialendoscopy Parotidectomy Parotidectomy Parenchymal Stones / Multiple Stones / Generalized fibrosis / Fistula Failed Sialoendoscopy Intraoperative Ultrasound Guidance Intraoperative Ultrasound Guidance Confirmation, Localization, Stone Fragmentation, Stenosis Guidance 1 11/6/2014 Preparation / Exposure 2 11/6/2014 Instrumentation 3 11/6/2014 Identification of Stensen’s Duct Papilla 4 11/6/2014 Punctal Dilation / Ductal Dilation 5 11/6/2014 Transoral Open Sialodochotomy / Sialodochoplasty Distal Stones / Stenosis Transoral Sialendoscopy Middle Duct - Hilar Stones / Stenosis Transfacial Open Duct Surgery (+/- Sialendoscopy) Impacted Stones / > 4-7mm Stones / Parenchymal stones Failed Sialendoscopy Parotidectomy Parenchymal Stones / Multiple Stones / Generalized fibrosis / Fistula Failed Sialoendoscopy Intraoperative Ultrasound Guidance Confirmation, Localization, Stone Fragmentation, Stenosis Guidance
    [Show full text]
  • Guide for Answering Theory Questions in MS Surgery
    WBUHS (2011-2015) MS- PAPER – I -IV Guide for Answering theory questions in MS Surgery Dr. Arkaprovo Roy ASSOCIATE PROFESSOR DEPARTMENT OF GENERAL SURGERY Dr. Arkaprovo Roy ASSOCIATE PROFESSOR DEPARTMENT OF GENERAL SURGERY MEDICAL COLLEGE AND HOSPITAL, KOLKATA THE WEST BENGAL UNIVERSITY OF HEALTH SCIENCES MS (General Surgery) Examination, 2015 PAPER I Time Allowed: 3 Hours Full Marks: 100 Attempt all questions 1. How will you assess the nutritional status of a surgical patient? Define and classify artificial nutritional support (ANS). Give an account of enteral nutrition and its advantages and drawbacks. 4+4+8+4 2. Describe the lymph node status in relation to spread of carcinoma stomach. Discuss in detail the different types of gastric carcinoma and prognosis in respect to lymph node harvest. 5+10+5 3. Write short notes of the following: 5x6 a) Pharmacological therapy in patients awaiting surgery for pheochromocytoma. b) Retroperitoneal fibrosis. c) Ethics and law in surgical practice. d) Pathophysiology of short bowel syndrome. e) Metabolic response to trauma. 4. Answer briefly on the following. 4x71/2 a) Laparoscopic versus conventional surgery in pregnancy. b) Component separation and role of blood components in surgery. c) Graft rejection in transplants. d) Immunohistochemistry. THE WEST BENGAL UNIVERSITY OF HEALTH SCIENCES MS (General Surgery) Examination, 2015 April 2015 PAPER I Time Allowed: 3 Hours Full Marks: 100 Attempt all questions 1. How will you assess the nutritional status of a surgical patient? Define and classify artificial nutritional support (ANS). Give an account of enteral nutrition and its advantages and drawbacks. 4+4+8+4 Answer.
    [Show full text]
  • 2015 Final Program
    AHNS 2015 Translational Research Meeting on Transforming Patient Care Through Innovative Research April 21-22, 2015 Sheraton Boston Hotel, 39 Dalton Street, Boston, MA 02199 FINAL PROGRAM www.ahns.info THE RESEARCH AND EDUCATION FOUNDATION OF THE AMERICAN HEAD AND NECK SOCIETY Dear Colleagues, As we all know, head and neck cancer is not one of the more “publicized” cancers and often overlooked by both the general public and research funding sources. However, we believe that this is slowly starting to change. With increased attention on head and neck cancer, the Research and Education Foundation believes this is an opportunity to strengthen and expand our impact. With your commitment to the Foundation, we can reverse the trend of declining funding for head and neck cancer research! Presently the Research and Education Foundation supports two research awards each year. We are proud to fund these grants but there are more to cover. We would like to create more opportunities for young clinicians and researchers to explore unique and innovative treatments which may one day lead to a cure. To do as much, the Foundation needs to increase its asset base. There are three targeted ways for you to support the Foundation which are designed to provide immediate revenue as well as to increase the capital base for the long term with the goal of generating increased annual income perpetually to support more research. The support opportunities include: 1. Legacy gifts, such as estate planning, single premium life insurance and charitable lead annuity trusts (CLATs), are meaningful ways to create continuous and sustainable growth for the Foundation in the years and decades to come.
    [Show full text]
  • Provider Type 20 Physician, MD., Osteopath Reimbursement Rates
    Provider Type 20 Physician, MD., Osteopath Reimbursement Rates Updated: July 1, 2015 The information contained in the schedule is made available to provide information and is not a guarantee by the State or the Department or its employees as to the present accuracy of the information contained herein. For example, coverage as well as an actual rate may have been revised or updated and may no longer be the same as posted on the website. Note: Procedure codes with a rate of $0.00 are reimbursed at 62% of Usual and Customary charges unless noted otherwise in Nevada Medicaid policy. CPT codes, descriptions and other data only are copyright © 2008 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CPT is a registered trademark ® of the American Medical Association. Current Dental Terminology, fourth edition (CDT) (including procedure codes, definitions (descriptors) and other data) is copyrighted by the American Dental Association. © 2008 American Dental Association. All rights reserved. Applicable FARS/DFARS apply. Proc Code Description Mod Rate 01953 ANESTH BURN EACH 9 PERCENT 0001 21.12 01996 HOSP MANAGE CONT DRUG ADMIN 0001 63.36 10021 FNA W/O IMAGE 0001 70.92 10022 FNA W/IMAGE 0001 65.39 10030 Guide cathet fluid drainage 0001 154.73 10040 ACNE SURGERY 0001 87.47 10060 DRAINAGE OF SKIN ABSCESS 0001 95.60 10061 DRAINAGE OF SKIN ABSCESS 0001 178.04 10080 DRAINAGE OF PILONIDAL CYST 0001 103.29 10081 DRAINAGE OF PILONIDAL CYST 0001 172.45 10120 REMOVE FOREIGN BODY 0001 103.22 10121 REMOVE FOREIGN BODY 0001 185.58
    [Show full text]
  • Micro‐Endoscopy of the Human Vas Deferens: a Feasibility Study of A
    ISSN: 2047-2919 ANDROLOGY ORIGINAL ARTICLE Correspondence: Micro-endoscopy of the human vas Matthias Trottmann, Department of Urology, University Hospitals Munich – Campus deferens: a feasibility study of a Grosshadern, 81377 Munich, Germany. E-mail: [email protected]. de novel device in several ex vivo models Keywords: azoospermia, infertility, seminal vesicles 1M. Trottmann, 1,2R. Sroka, 3C. Braun, 4B. Liedl, 5H. Schaaf, 3M. Graw, Received: 17-Apr-2016 1A. J. Becker, 1C. G. Stief and 1W. Y. Khoder Revised: 17-Jul-2016 1 2 Accepted: 2-Aug-2016 Department of Urology, Klinikum Grosshadern, University of Munich, Munich, Germany, LIFE Centre, University Hospital of Munich, Munich, Germany, 3Department for Forensic Medicine, University of Munich, Munich, Germany, 4Department of Urogenital Surgery, Clinics for Surgery doi: 10.1111/andr.12282 Munich-Bogenhausen, Munich, Germany, and 5Polydiagnost GmbH, Hallbergmoos, Germany SUMMARY The aim of this study was to show limitation as well as potential of micro-endoscopy techniques as an innovative diagnostic and therapeutic approach in andrology. Two kinds of custom-made micro-endoscopes (ME) were tested in ex vivo vas deferens specimen and in post-mortem whole body. The semi-rigid ME included a micro-optic (0.9 mm outer diameter [OD], 10.000 pixels, 120° vision angle [VE], 3–20 mm field depth [FD]) and an integrated fibre-optic light source. The flexible ME was composed of a micro-optic (OD = 0.6 mm, 6.000 pixels, 120° VE, 3–20 mm FD). The ex vivo study included retrograde investigation of the vas deferens (surgical specimen n = 9, radical prostatectomy n = 3).
    [Show full text]
  • Head and Neck Surgery Report on Clinical and Scientific Innovations Newyork-Presbyterian a Top 5 Hospital in the Nation
    NewYork-Presbyterian Otolaryngology – Head and Neck Surgery Report on Clinical and Scientific Innovations NewYork-Presbyterian A Top 5 Hospital in the Nation NewYork-Presbyterian Otolaryngology – Head and Neck Surgery New York’s #1 Hospital Report on Clinical and Scientific Innovations 19 Years in a Row Welcome 1 Otolaryngology – Head and Neck Surgery Leaders in Voice Preservation and Recovery Center for Voice and Swallowing 2 Sean Parker Institute for the Voice 4 Leadership Center for the Performing Artist 5 Lawrence R. Lustig, MD Pioneering the Understanding and Otolaryngologist-in-Chief Michael G. Stewart, MD, MPH Treatment of Hearing Loss 6 Department of Otolaryngology – Otolaryngologist-in-Chief Head and Neck Surgery Department of Otolaryngology – Innovative Treatments for Allergic Rhinitis NewYork-Presbyterian/ Head and Neck Surgery and Other Nasal Disorders 9 NewYork-Presbyterian/ Columbia University Advancing Minimally Invasive and Skull Base Surgery 11 Irving Medical Center Weill Cornell Medical Center Novel Approaches to Head and Neck Surgery Howard W. Smith Professor and Chair Professor and Chairman Department of Otolaryngology – Department of Otolaryngology – Exploring Molecular Drivers of Head and Neck Cancers 12 Head and Neck Surgery Head and Neck Surgery Facial Plastic Surgery 13 Columbia University Weill Cornell Medicine Pediatric Tracheostomy Care 13 Irving Medical Center Sleep Apnea Management 15 Leading the Way in Education 16 Make an Appointment 17 NewYork-Presbyterian 18 For More Information nyp.org Welcome Dear Colleague: The Departments of Otolaryngology – Head and Neck Surgery at NewYork- Presbyterian/Columbia University Irving Medical Center and NewYork- Presbyterian/Weill Cornell Medical Center feature world-class teams who provide comprehensive ear, nose, and throat care and head and neck surgical services for patients of all ages.
    [Show full text]
  • Bronchial Thermoplasty for Severe Asthma
    Health Evidence Review Commission’s Value-based Benefits Subcommittee December 13, 2012 Meridian Park Hospital Community Health Education Center, Room 117B&C 19300 SW 65th Avenue, Tualatin, OR 97062 Section 1 Agenda AGENDA VALUE-BASED BENEFITS SUBCOMMITTEE December 13, 2012 8:30am - 2:30pm Meridian Park Room 117B&C Community Health Education Center Tualatin, OR 97062 A working lunch will be served at approximately 12:00 PM All times are approximate I. Call to Order, Roll Call, Approval of Minutes – Lisa Dodson 8:30 AM II. Staff report – Ariel Smits, Cat Livingston, Darren Coffman 8:35 AM III. Straightforward 8:45 AM A. Straightforward issues table B. Low back pain coding specifications C. Bariatric surgery coding specification IV. New CPT Codes 8:50 AM A. 2013 CPT codes A. 2013 Genetic testing CPT codes B. 2013 Psychiatric CPT codes B. 2013 HCPCS codes C. 2013 CDT codes A. Dental guideline changes V. New discussion items 11:00 AM A. Silver nitrate treatments for dental caries B. Pseudobulbar affect VI. Coverage Guidances for review 12:00 PM A. Viscosupplementation for osteoarthritis of the knee B. Percutaneous interventions for low back pain C. Management of chronic otitis media in children VII. Previous Discussion Items 1:00 PM A. Puberty suppression for transgendered youth VIII. Guidelines 1:45 PM A. Guideline note 44, Menstrual Bleeding Disorders B. Prenatal genetic testing guideline IX. Public comment 2:25 PM X. Adjournment 2:30 PM Section 2 Minutes Value-based Benefits Subcommittee Recommendations Summary For Presentation to: Health Evidence Review Commission on October 11, 2012 For specific coding recommendations and guideline wording, please see the text of the (10/11/12) VbBS minutes.
    [Show full text]